Mauna Kea Technologies Sa Class O · EURONEXT:ALMKT
Mauna Kea Technologies Sa Class O — Investor Presentation (August 2023)
24 slides from Mauna Kea Technologies Sa Class O's investor presentation, August 2023
Slide 1: Corporate Presentation – August 2023
Corporate Presentation – August 2023
Slide 2: Disclaimer
Disclaimer • This document has been prepared by Mauna Kea Technologies (the "Company") and is provided for information purposes only. • The information and opinions contained in this document speak only as of the date of this document and may be updated, supplemented, revised, verified or amended, a
Slide 3: See Cells. Change Lives.
See Cells. Change Lives. By creating the first platform to image the human body at the cellular level, we’ve changed the way physicians see and treat their patients. Mission With Cellvizio®, our advanced cellular imaging platform, we provide partners and providers with the most advanced and proven i
Slide 4: The Future of Cellvizio is Built on Strong Pillars
The Future of Cellvizio is Built on Strong Pillars ® Unique and Extensive Strong pipeline of Long-standing Strong intellectual differentiated knowledge of potential strategic collaborations with property portfolio imaging platform procedures partnerships industry leaders • Proprietary imaging • 250+
Slide 5: Major milestones achieved over the past 18 months
Major milestones achieved over the past 18 months Improved leadership 1 More compact highly functioning team with key additions Signed major agreement with Tasly Pharmaceutical 2 Validation of partnership strategy to develop new markets Improved liquidity with non-dilutive financing Strong direct sa
Slide 6: Our Seasoned Team has Decades of Combined Industry Experience
Our Seasoned Team has Decades of Combined Industry Experience Sacha Loiseau, Ph.D. Chairman and CEO Founder Nathalie Lecoq Côme de La Tour du Pin Chief Operating Officer Chief Financial Officer Bruno Villaret François Lacombe, Ph.D. Vice President, International Sales Chief Scientific Officer Daryl
Slide 7: Cellvizio: a Proprietary In Vivo Cellular Imaging Platform
Cellvizio : a Proprietary In Vivo Cellular Imaging Platform ® The only real-time probe-based in vivo functional and dynamic cellular imaging platform The Cellvizio System Portfolio of Miniprobes Confocal Miniprobes™ Capital equipment Consumables © 2023 Mauna Kea Technologies 7
Slide 8: From Cellvizio 100S to Cellvizio Gen3
From Cellvizio 100S to Cellvizio Gen3 • Radically new platform architecture • Much reduced footprint and improved mobility • Acclaimed interface, workflow, and connectivity • Roadmap to open platform for AI modules and other software enhancements • 20+ installations of Gen3 (out of 200) in the US wi
Slide 9: Cellvizio Provides Real-Time In Situ Functional Cellular Imaging
Cellvizio Provides Real-Time In Situ Functional Cellular Imaging From H&E histology… ‣ One image ‣ Static view …to Cellvizio® ‣ Hundreds of live microscopic images per minute ‣ A dynamic functional view of biological tissues in real time BRAIN ESOPHAGUS COLON “Patients are better served if biopsies
Slide 10: Investment Thesis
Investment Thesis In 2022, building on a decade of invaluable experience and investments, the Company made a strategic decision to pivot from direct marketing to strategic partnerships with leading medtech/pharma firms and made already significant process Strategic Partnerships Cost Efficiency New p
Slide 11: Large Market Opportunities
Large Market Opportunities Urology (Endourology / Surgery) GI / IBD / IBS $2.2B+ High $1.0B $1.0B /yr /yr /yr GI / Barrett’s Esophagus & $0.5B Stomach cancer $0.5B/yr $100M /yr /yr MARKET SIZE Low Interventional Neurosurgery GI / Pancreatic cysts Pulmonology MATURITY OF APPLICATION < ONCOLOGY < IBD/
Slide 12: Extensive Pipeline of Indications for Potential Strategic Partnerships
Extensive Pipeline of Indications for Potential Strategic Partnerships CLINICAL REGULATORY IN COMMERCIAL APPLICATION ECOSYSTEM DEVELOPMENT APPROVAL MARKET PARTNERSHIP PANCREATIC CYSTS #needles #AI GLOBAL DIRECT OPEN ESOPHAGEAL & #endoscopy STOMACH CANCERS GLOBAL DIRECT OPEN #AI ONCOLOGY LUNG CANCER
Slide 13: An Increasingly Sophisticated Platform Fully Aligned with Our Partners' Key Needs
An Increasingly Sophisticated Platform Fully Aligned with Our Partners' Key Needs MOLECULAR CANCER IMAGING ROBOTIC ASSISTED IMAGING X ARTIFICIAL INTELLIGENCE BUILD CELLVIZIO IMAGING DATASETS • In vivo endoscopic visualization of • Integrated navigation targeted cancer cells and data capture Cellvizi
Slide 14: Our New Business Strategy Already Being Validated
Our New Business Strategy Already Being Validated JV and Licensing agreement with Tasly Pharmaceutical $10 million upfront cash contribution to Mauna Kea, of which $9m received in January / May 2023 JV now incorporated in Zhejiang province with $35m registered capital Mauna Kea to own 44.1% of JV in
Slide 15: 1. Expanding the Chinese Market
1. Expanding the Chinese Market Installed base in China Building on solid installed base of 46 Liaoning - 2 Beijing & Tianjin - 7 systems in Eastern China and strong KOL Shandong - 2 support Inner Mongolia - 1 Hubei - 2 Expansion to entire territory with Tasly Shanxi - 1 Sichuan & Chongqing - 3 Acce
Slide 16: 2. Launching a Dedicated Cellvizio Platform for Neurosurgery
2. Launching a Dedicated Cellvizio Platform for Neurosurgery A key application 10 years in the making Zeiss launches the Publication by Pr. Guyotat et al on Convivo Confocal Neuro-endomicroscope 2023 stereotactic neurologic applications of Cellvizio 2022 2020 2021 Tasly Mauna Kea Medical Engineering
Slide 17: H1 2023 Financial Update
H1 2023 Financial Update © 2023 Mauna Kea Technologies 17
Slide 18: Main Achievements in the First Half of 2023
Main Achievements in the First Half of 2023 CORPORATE ACTIVITY PARTNERSHIP CELLVIZIO Strengthened Excellent Business Delivering on Our Platform Leadership Team Performance Strategy enhancement Strong acceleration of Launch of JV with Tasly Appointment of a Chief sales growth notably in in China Laun
Slide 19: Strong Revenue Growth in Q2 and H1 2023
Strong Revenue Growth in Q2 and H1 2023 Q2 2023 Revenue in Q2 and H1 2023 vs 2022 In thousands of euros €6.8m +77% €7 000 revenue growth driven by a +100% increase in sales in the United States and by licensing €5 250 €3 301 revenues from the JV with Tasly €3 500 €2.7m H1 2023 €499 €1 750 €3 397 €3
Slide 20: Sales by Segment in Q2 2023
Sales by Segment in Q2 2023 Systems Strong growth in the United States and Europe, with 4 €699 systems sold, despite the negative impact from the +93% transfer of Chinese business to the JV with Tasly €363 Consumables Strong acceleration in the US PPU business, up 50% €1 100 despite uorescein supply
Slide 21: Sales by Geography in Q2 2023
Sales by Geography in Q2 2023 United States Excellent momentum in the United States, with sales €1 669 doubling, driven both by systems and probes, and by +100% the acceleration of the PPU business €833 €481 EU & RoW Business boosted by system sales, including the €358 +34% installation of a Cellviz
Slide 22: The Group's Priorities
The Group's Priorities Drive Business Increase Ensure Build High-Value Momentum Operational Technological Partnerships Performance Excellence Intensify the adoption Develop new features Establish high-pro le of the next-generation twice a year Optimize cost structure JV in China Cellvizio Integrate
Slide 23: Stock and Shareholding Information
Stock and Shareholding Information Stock Market Data Analyst Coverage • Listed on Euronext Growth Paris GILBERT DUPONT Founders & Guillaume Cuvillier Management • Number of outstanding shares: Other Institutionals 48,668,395 2% PORTZAMPARC 11% • Market cap: Mohamed Kaabouni €30M 22% Johnson & Johnso
Slide 24: Our Growth Strategy Benefits from 15 years of Global Multidisciplinary Clinical Community Building
Our Growth Strategy Benefits from 15 years of Global Multidisciplinary Clinical Community Building. © 2023 Mauna Kea Technologies 24
Mauna Kea Technologies — Investor Presentation (August 2023) on 6ix